Login / Signup

Evaluation of mRNA-1273 Vaccine in Children 6 Months to 5 Years of Age.

Larry J AndersonC Buddy CreechVladimir BerthaudArin PiramzadianKimball A JohnsonMarcus ZervosFredric GarnerCarl GriffinKhozema PalanpurwalaMark TurnerJeffrey GerberRichard L BennettKashif AliMadhavi AmpajwalaGary BermanJennifer NayakCarey ChronisBarbara RizzardiWilliam J MullerChristopher A SmithGeorge FuchsDaniel HsiaJoanne E TomassiniDianne DeLuciaCaroline ReuterBarbara KuterXiaoping ZhaoWeiping DengHonghong ZhouDaniela Ramirez SchremppKelly HautzingerBethany GirardKaren SlobodRoderick McPheeRolando PajonAnne AuninsRituparna DasJacqueline M MillerSabine Schnyder Ghamloushnull null
Published in: The New England journal of medicine (2022)
Two 25-μg doses of the mRNA-1273 vaccine were found to be safe in children 6 months to 5 years of age and elicited immune responses that were noninferior to those in young adults. (Funded by the Biomedical Advanced Research and Development Authority and National Institute of Allergy and Infectious Diseases; KidCOVE ClinicalTrials.gov number, NCT04796896.).
Keyphrases
  • young adults
  • infectious diseases
  • immune response
  • binding protein
  • quality improvement
  • childhood cancer
  • dendritic cells
  • toll like receptor